Top 5 Drug Type | Count |
---|---|
Small molecule drug | 42 |
Chemical drugs | 14 |
Monoclonal antibody | 3 |
Peptide Conjugate Radionuclide | 2 |
Synthetic peptide | 2 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication- |
Inactive Indication- |
Drug Highest PhaseIND Application |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication- |
Inactive Indication- |
Drug Highest PhaseIND Application |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Jun 2025 |
Sponsor / Collaborator |
Start Date15 Jan 2025 |
Sponsor / Collaborator |
Start Date01 Jan 2025 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
HY-0902 | Hyperuricemia More | Phase 2 |
K-5a2 ( RT ) | HIV Infections More | IND Approval |
Qβ-MUC1-Tf ( MUC1 ) | Melanoma More | Preclinical |
GC-14 ( SARS-CoV-2 Mpro ) | COVID-19 More | Preclinical |
HDAC inhibitors(Shandong University) ( HDACs ) | Neoplasms More | Preclinical |